Quick Answer
Skye Bioscience, Inc. reported R&D Expense of $6.01 million for fiscal year 2022.
Skye Bioscience, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2022 | $6.01M | +105.1% |
| 2021 | $2.93M | +50.8% |
| 2020 | $1.94M | -13.1% |
| 2019 | $2.24M | +578.2% |
| 2018 | $330.0K | +6.0% |
| 2017 | $311.3K | -66.8% |
| 2016 | $939.0K | +63.0% |
| 2015 | $576.1K | +153.2% |
| 2014 | $227.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2023 | $1.79M | +25.3% | +50.9% |
| March 31, 2023 | $1.18M | -6.4% | -33.5% |
| September 30, 2022 | $1.78M | +443.7% | +24.8% |
| June 30, 2022 | $1.43M | +62.1% | +12.8% |
| March 31, 2022 | $1.27M | +107.6% | +286.2% |
| September 30, 2021 | $327.7K | -5.3% | -62.8% |
| June 30, 2021 | $880.7K | +105.5% | +44.5% |
| March 31, 2021 | $609.7K | -23.8% | +76.1% |
- Skye Bioscience, Inc. showed an increase of +105.1% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2022 period, Skye Bioscience, Inc.’s r&d expense has grown by 2542.6% (from $227.5 thousand to $6.01 million).
- The most recent figure is from Skye Bioscience, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 31, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: